Xeris Biopharma Holdings financials
$9.98+1.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M |
| Gross profit | $249.3M | $166.2M | $135.3M | $87.6M | $36.3M |
| Gross margin | 85.4% | 81.9% | 82.5% | 79.5% | 73.1% |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$85.1M | -$115.2M |
| Net income | $554.0K | -$54.8M | -$62.3M | -$94.7M | -$122.7M |
| Net margin | 0.2% | −27.0% | −38.0% | −85.9% | −247.5% |
| Diluted EPS | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
| EBITDA | $37.1M | -$21.6M | -$31.7M | -$69.7M | -$113.3M |
| Operating cash flow | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M |
| Free cash flow | $27.9M | -$37.8M | -$49.3M | -$103.4M | -$96.6M |
| Diluted shares | 172.7M | 146.8M | 137.7M | 135.6M | 79.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $111.0M | $71.6M | $67.4M | $122.0M | $67.3M |
| Short-term investments | $0.00 | $0.00 | $5.0M | $0.00 | $35.2M |
| Total debt | $220.3M | $232.1M | $190.9M | $203.9M | $88.1M |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M |
| Shareholders' equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology